258P Adjuvant abemaciclib for early breast cancer: Learning to improve adherence. Real-world evidence from a multicentric cooperative group

ESMO Open 2026 Open access

Read full text
Authors: P. Mandó, G. Guaygua Loayza, A. Borello, M.A. Lutteral, M.F. Illia, M.A. Nunell, L. Cermignani, I. Robledo Salas, F. S. E. Monteagudo, L. Gonzalez, M.B. Cieplinski, J. Mandrile
+8 more A. Mazzotta, M.C.A. Elaskar, M.A. Iriso, M.B. Montenegro, M. G. Ferreira, A. gallardo, M.D. Broilo, F. Waisberg
DOI: 10.1016/j.esmoop.2026.107211
Cited by: 1

Abstract

Adjuvant CDK4/6 inhibitors are standard of care for patients with intermediate- and high-risk HR+/HER2– early breast cancer. However, treatment-related toxicities and quality-of-life impairment may affect adherence. Dose adjustments are commonly used to improve tolerance, particularly in older patients, though real-world data are limited.

Fields of Study & Subjects

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Cancer-related Molecular Pathways

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
107211–107211
Publication date
1 May 2026
Language
EN